DBV Technologies | DBVT - Beneficio Bruto En Ventas





Beneficio Bruto En Ventas Cambio Fecha
Acadia Pharmaceuticals USD 257.76M 778K 2025-12
Alnylam Pharmaceuticals USD 829.31M 219.56M 2025-12
Amarin USD 23.17M 961K 2025-12
BioCryst Pharmaceuticals USD 153.05M 4.16M 2025-12
BioMarin Pharmaceutical USD 713.01M 81.81M 2025-12
DBV Technologies USD 2.77M 33.21M 2025-09
Esperion Therapeutics USD 140.59M 94.57M 2025-12
Halozyme Therapeutics USD 281.77M 2.41M 2025-09
Incyte USD 1.39B 118.68M 2025-12
Insmed USD 217.69M 106.25M 2025-12
Ionis Pharmaceuticals USD 195M 40M 2025-12
Neurocrine Biosciences USD 787.9M 7M 2025-12
PTC Therapeutics USD 148.38M 39.31M 2025-12
Sarepta Therapeutics USD 43.55M 204.36M 2025-12
Ultragenyx Pharmaceutical USD 178M 46.06M 2025-12
United Therapeutics USD 315.5M 286.6M 2025-12